Follicular lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 27
• CD20 14
• BTK 9
• BCL-2 5
• CD22 5
• MYC 3
• EZH2 2
• PD-1 3
• PI3K 0
• PD-L1 1
• TP53 0
• CD40 0
• CD47 0
• CXCR4 0
• EGFR 0
• HDAC 0
• ABL1 0
• AKT 0
• ALK 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD30 0
• CSF1R 1
• G6PD 0
• IL-1 0
• IL-15 0
• IL-17 0
• LAG-3 0
• MEK 0
• PPAR 0
• STAT3 0
• TFEB 0
• TIGIT 1
• TIM-3 0

24 of 376 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Making patient-derived tumor organoids a reliable cancer therapy testing platform (TUMORGPLAT)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €245,490· until Dec 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in the Tissue Microenvironment

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €296,296· until Apr 2027· 2 countries

3 of 3 running projects, newest first. Listed amounts together: €758.0k.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

  NCT04855253· Masonic Cancer Center, University of Minnesota· Updated 4 Nov 2026

  “Accrual met”Registry text, quoted unchanged. Source

• Terminated

  64Cu-LLP2A for Imaging Hematologic Malignancies

  NCT06636175· Washington University School of Medicine· Updated 16 Oct 2026

  “Loss of further funding”Registry text, quoted unchanged. Source

• Suspended

  ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

  NCT07098364· Fred Hutchinson Cancer Center· Updated 11 Sept 2026

  “Insufficient funding”Registry text, quoted unchanged. Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Updated 14 Jul 2026

  “This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

  NCT05453396· University of Washington· Updated 15 Jun 2026

  “The trial closed early due to slow accrual.”Registry text, quoted unchanged. Source

• Terminated

  Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

  NCT01962636· Masonic Cancer Center, University of Minnesota· Updated 20 May 2026

  “No longer a research question to answer.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies

  NCT07282548· Ipsen· Updated 29 Apr 2026

  “Withdrawn prior to enrolment after review of updated safety data”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

  NCT07030699· Memorial Sloan Kettering Cancer Center· Updated 7 Apr 2026

  “Lack of accrual”Registry text, quoted unchanged. Source

• Terminated

  Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

  NCT05618366· Weill Medical College of Cornell University· Updated 2 Apr 2026

  “Low accrual”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

  NCT06313996· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Updated 18 Mar 2026

  “Replaced with another clinical trial.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Regeneron Pharmaceuticals· Source

• A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy

  NCT06510361· Beth Israel Deaconess Medical Center· Source

• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

  NCT05627245· National Cancer Institute (NCI)· Source

• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

  NCT04799275· National Cancer Institute (NCI)· Source

• A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Regeneron Pharmaceuticals· Source

• Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· National Cancer Institute (NCI)· Source

• An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

  NCT03930953· Celgene Corp.· Source

• A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· Merck Sharp & Dohme LLC· Source

• A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Merck Sharp & Dohme LLC· Source

• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Whole Genome Sequencing 1
• Flow Cytometry 2
• Immunohistochemistry 12
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 2
• Cohort Studies 6
• Genome-Wide Association Study 4

• Splice-site mutations in POU2AF1 are associated with B-cell lymphomagenesis and therapeutic response.

  Sci Rep, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.